Market Overview:
The global community acquired pneumonia (CAP) market is expected to register a CAGR of 5.8% during the forecast period, 2018-2030. The market growth can be attributed to the increasing incidence of CAP, rising demand for better healthcare facilities and growing awareness about CAP. Based on type, the global community acquired pneumonia (CAP) market is segmented into chest x-ray/radiography, sputum gram stain and/or culture, blood cultures and others. The chest x-ray/radiography segment is expected to account for the largest share in terms of revenue in 2018. This can be attributed to its high usage rates for diagnosis of CAP across hospitals and clinics worldwide. Based on application, the global community acquired pneumonia (CAP) market is segmented into hospitals and clinics and others segments. The hospitals & clinics segment accounted for majority share in 2017 owing to rising number of hospital admissions due to CAP globally.
 Industry Outlook.svg)
Product Definition:
CAP is a type of pneumonia that is not caused by infection in a hospital or other health care setting. It can be caused by many types of bacteria, viruses, or fungi.
Chest X-ray/Radiography:
According to the WHO, globally around 5 million people die due to community acquired pneumonia (CAP) each year. It is one of the leading causes of death in children under five years of age. The incidence and prevalence are expected to increase with global warming and rising air pollution levels.
Sputum Gram Stain and/or Culture:
Sputum gram stain and/or culture is used to differentiate between bacterial pneumonia (bacterial infection of the lungs) and viral pneumonia (viral infection of the lungs). Gram stain is performed on sputum sample to see if it contains bacteria or not. If there are many bacteria in the sample, then that means that there is a high chance of bacterial pneumonia.
Application Insights:
The others segment captured the largest revenue share in 2016 and this trend is anticipated to continue over the forecast period. This can be attributed to growing awareness about CAP, increasing incidence of hospital-acquired pneumonia (HA-P), and rising expenditure on healthcare. The hospitals and clinics application segment is expected to grow at a significant rate owing to availability of advanced healthcare facilities in most countries, which makes it convenient for patients with pneumonia symptoms seek treatment at a hospital or clinic.
In addition, there are other less common applications such as primary care settings that may not have sufficient capacity but still manage to capture substantial market share due to high demand for management of pneumonia cases among patients presenting with typical chest X-ray signs or symptoms. These settings also offer outpatient management services which contributes significantly towards overall revenue generation in these segments.
Regional Analysis:
Infectious diseases continue to be the leading cause of morbidity and mortality in many parts of the world. The global community acquired pneumonia (CAP) market is expected to witness a significant rise over the forecast period owing to increasing prevalence of respiratory infections, rising awareness about early diagnosis, improved access to healthcare facilities and supportive government initiatives.
The Asia Pacific region accounted for a revenue share of 23.1% in 2017 due to high incidence rates associated with infectious diseases coupled with low awareness levels pertaining towards disease diagnosis and treatment in this region. In addition, rapidly growing medical tourism industry is also expected boost growth rate during the forecast period.
Growth Factors:
- Increasing incidence of pneumonia: The incidence of pneumonia is increasing due to various factors such as the increase in the aging population, changes in lifestyle, and increased exposure to pathogens. This is expected to drive the growth of the CAP market.
- Rising demand for effective and safe antibiotics: The growing prevalence of antibiotic-resistant strains of bacteria has led to an increased demand for effective and safe antibiotics. This is expected to drive the growth of the CAP market.
- Growing awareness about pneumococcal vaccines: There is a growing awareness among people about pneumococcal vaccines that can help prevent CAP caused by Streptococcus pneumoniae bacteria. This is expected to drive the growth of the CAP market.
Scope Of The Report
Report Attributes
Report Details
Report Title
Community Acquired Pneumonia (CAP) Market Research Report
By Type
Chest X-ray/Radiography, Sputum Gram Stain and/or Culture, Blood Cultures
By Application
Hospitals and Clinics, Others
By Companies
Pfizer, Astrazeneca, Bioaegis Therapeutics, Biotest, C10 Pharma, Kyorin Pharmaceutical, Melinta Therapeutics, Merck, Nabriva Therapeutics, Paratek Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
166
Number of Tables & Figures
117
Customization Available
Yes, the report can be customized as per your need.
Global Community Acquired Pneumonia (CAP) Market Report Segments:
The global Community Acquired Pneumonia (CAP) market is segmented on the basis of:
Types
Chest X-ray/Radiography, Sputum Gram Stain and/or Culture, Blood Cultures
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals and Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Astrazeneca
- Bioaegis Therapeutics
- Biotest
- C10 Pharma
- Kyorin Pharmaceutical
- Melinta Therapeutics
- Merck
- Nabriva Therapeutics
- Paratek Pharmaceuticals
 Market Overview.svg)
Highlights of The Community Acquired Pneumonia (CAP) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Chest X-ray/Radiography
- Sputum Gram Stain and/or Culture
- Blood Cultures
- By Application:
- Hospitals and Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Community Acquired Pneumonia (CAP) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
CAP is a lung infection caused by the bacterium Streptococcus pneumoniae. It most often affects people over 65 years old, but can occur at any age. CAP is most common in winter and spring, when cold weather and increased exposure to respiratory viruses increase the risk of infection. Symptoms of CAP include fever, shortness of breath, coughing up mucus, and chest pain. Treatment typically includes antibiotics to fight the bacteria and rest for patients who are not able to take their medications orally.
Some of the major companies in the community acquired pneumonia (cap) market are Pfizer, Astrazeneca, Bioaegis Therapeutics, Biotest, C10 Pharma, Kyorin Pharmaceutical, Melinta Therapeutics, Merck, Nabriva Therapeutics, Paratek Pharmaceuticals.
The community acquired pneumonia (cap) market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Community Acquired Pneumonia (CAP) Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Community Acquired Pneumonia (CAP) Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Community Acquired Pneumonia (CAP) Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Community Acquired Pneumonia (CAP) Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Community Acquired Pneumonia (CAP) Market Size & Forecast, 2018-2028
4.5.1 Community Acquired Pneumonia (CAP) Market Size and Y-o-Y Growth
4.5.2 Community Acquired Pneumonia (CAP) Market Absolute $ Opportunity
Chapter 5 Global Community Acquired Pneumonia (CAP) Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Community Acquired Pneumonia (CAP) Market Size Forecast by Type
5.2.1 Chest X-ray/Radiography
5.2.2 Sputum Gram Stain and/or Culture
5.2.3 Blood Cultures
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Community Acquired Pneumonia (CAP) Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Community Acquired Pneumonia (CAP) Market Size Forecast by Applications
6.2.1 Hospitals and Clinics
6.2.2 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Community Acquired Pneumonia (CAP) Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Community Acquired Pneumonia (CAP) Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Community Acquired Pneumonia (CAP) Analysis and Forecast
9.1 Introduction
9.2 North America Community Acquired Pneumonia (CAP) Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Community Acquired Pneumonia (CAP) Market Size Forecast by Type
9.6.1 Chest X-ray/Radiography
9.6.2 Sputum Gram Stain and/or Culture
9.6.3 Blood Cultures
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Community Acquired Pneumonia (CAP) Market Size Forecast by Applications
9.10.1 Hospitals and Clinics
9.10.2 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Community Acquired Pneumonia (CAP) Analysis and Forecast
10.1 Introduction
10.2 Europe Community Acquired Pneumonia (CAP) Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Community Acquired Pneumonia (CAP) Market Size Forecast by Type
10.6.1 Chest X-ray/Radiography
10.6.2 Sputum Gram Stain and/or Culture
10.6.3 Blood Cultures
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Community Acquired Pneumonia (CAP) Market Size Forecast by Applications
10.10.1 Hospitals and Clinics
10.10.2 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Community Acquired Pneumonia (CAP) Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Community Acquired Pneumonia (CAP) Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Community Acquired Pneumonia (CAP) Market Size Forecast by Type
11.6.1 Chest X-ray/Radiography
11.6.2 Sputum Gram Stain and/or Culture
11.6.3 Blood Cultures
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Community Acquired Pneumonia (CAP) Market Size Forecast by Applications
11.10.1 Hospitals and Clinics
11.10.2 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Community Acquired Pneumonia (CAP) Analysis and Forecast
12.1 Introduction
12.2 Latin America Community Acquired Pneumonia (CAP) Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Community Acquired Pneumonia (CAP) Market Size Forecast by Type
12.6.1 Chest X-ray/Radiography
12.6.2 Sputum Gram Stain and/or Culture
12.6.3 Blood Cultures
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Community Acquired Pneumonia (CAP) Market Size Forecast by Applications
12.10.1 Hospitals and Clinics
12.10.2 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Community Acquired Pneumonia (CAP) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Community Acquired Pneumonia (CAP) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Community Acquired Pneumonia (CAP) Market Size Forecast by Type
13.6.1 Chest X-ray/Radiography
13.6.2 Sputum Gram Stain and/or Culture
13.6.3 Blood Cultures
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Community Acquired Pneumonia (CAP) Market Size Forecast by Applications
13.10.1 Hospitals and Clinics
13.10.2 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Community Acquired Pneumonia (CAP) Market: Competitive Dashboard
14.2 Global Community Acquired Pneumonia (CAP) Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Astrazeneca
14.3.3 Bioaegis Therapeutics
14.3.4 Biotest
14.3.5 C10 Pharma
14.3.6 Kyorin Pharmaceutical
14.3.7 Melinta Therapeutics
14.3.8 Merck
14.3.9 Nabriva Therapeutics
14.3.10 Paratek Pharmaceuticals
